EUVIMEDEUVIMED entdecken
Crossref

Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension

Peng Hou, Haiming Chen, Sihao Liang, Wenliang Guo, Ruiyue Zhao, Huailu Pan, Haimin Liu, Youcai Li, Jie Lv, Kaixiang Zhong, Miao Ke, Yimin Fu und 3 weitere

Journal of Nuclear Medicine · 2025-01 · 66 (1) · 98-103

DOI: 10.2967/jnumed.124.268376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.01.2025. Verfasst von Peng Hou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fibrosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to investigate the feasibility of using 18F-labeled fibroblast activation protein inhibitor (FAPI) PET/CT in assessing the fibrotic remodeling of the pulmonary artery (PA) and the right ventricle (RV) in pulmonary arterial hypertension (PAH).

Methods

In a rat model of monocrotaline-induced PAH, rats were euthanized at different time points for tissue analysis (fibroblast activation protein immunofluorescence and Masson's trichrome staining) after completing 18F-FAPI PET/CT and hemodynamic measurements. Thirty-eight PAH patients were enrolled to participate in 18F-FAPI PET/CT imaging, with right heart catheterization and echocardiography performed within 1 wk to assess pulmonary hemodynamics and cardiac function.

Results

In the animal experiments, RV systolic pressure in monocrotaline rats increased from day 14 to day 21 after injection. 18F-FAPI uptake and fibroblast activation protein expression in the myocardium and lungs peaked on day 14 after injection. Collagen deposition in the RVs and peripheral PAs of monocrotaline rats progressively deteriorated from day 14 to day 21. In the human PAH study, 18F-FAPI PET/CT imaging identified varying degrees of 18F-FAPI uptake in the myocardium and proximal and distal PAs, correlating with clinical, RV function, and pulmonary hemodynamic parameters. Among the 5 follow-up patients who underwent a second 18F-FAPI PET/CT scan after 6 mo (range, 4-9 mo) of PAH-targeted therapy, 3 demonstrated reduced 18F-FAPI uptake, corresponding with clinical improvement.

Conclusion

18F-FAPI PET/CT imaging is feasible for visualizing the remodeling of the PA and the RV in PAH. Although it offers promise for assessing disease-related changes, its role in evaluating disease severity and monitoring therapeutic efficacy requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFibrosisAnimalsRatsMaleHumansFemaleMiddle AgedPulmonary Arterial HypertensionMolecular ImagingAdultRats, Sprague-DawleySerine EndopeptidasesGelatinasesMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

18F-FAPIPET/CTpulmonary arterial hypertensionpulmonary arteryright ventricle

Substanzen

Serine EndopeptidasesGelatinasesMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Department of Nuclear Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Re…
  • Department of Critical Care Medicine, Heyuan People's Hospital, Heyuan, China.
  • Department of Nuclear Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; gyfyyhc@126.com 71lu@163.com.

Zitieren

APA

Hou, P., Chen, H., Liang, S., Guo, W., Zhao, R., Pan, H., Liu, H., Li, Y., Lv, J., Zhong, K., Ke, M., Fu, Y., Zhong, H., Wang, X., & Hong, C. (2025). Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension. Journal of Nuclear Medicine, 66(1), 98-103. https://doi.org/10.2967/jnumed.124.268376

Vancouver

Hou P, Chen H, Liang S, Guo W, Zhao R, Pan H, et al. Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension. Journal of Nuclear Medicine. 2025;66(1):98-103. doi:10.2967/jnumed.124.268376

BibTeX
@article{Hou2025,
  author = {Hou, Peng and Chen, Haiming and Liang, Sihao and Guo, Wenliang and Zhao, Ruiyue and Pan, Huailu and Liu, Haimin and Li, Youcai and Lv, Jie and Zhong, Kaixiang and Ke, Miao and Fu, Yimin and Zhong, Huizhen and Wang, Xinlu and Hong, Cheng},
  title = {Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {1},
  pages = {98--103},
  doi = {10.2967/jnumed.124.268376}
}
Kostenlos starten →